

#### PRIOR AUTHORIZATION REQUEST FORM EOC ID:

### Juvenile Idiopathic Arthritis (OAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable	):
Drug Name and Strength:		
Directions / SIG:		
Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.		
Q1. What drug is being requested?  Actemra (tocilizumab) - IV Formulation Enbrel (etanercept) Humira (adalimumab) Orencia (abatacept)- IV Formulation Orencia (abatacept)- SubQ Formulation		
Q2. What diagnosis is this drug being prescribed for (pick one)?  POLYARTICULAR juvenile idiopathic arthritis (JIA) [proceed to Q3-8]  SYSTEMIC juvenile idiopathic arthritis (JIA) [proceed to Q3-4, 9]  Other		
Q3. Please provide ICD code(s) for diagnosis.		
Q4. Please indicate location of administration.  Home Long Term Care (LTC) facility Physician office (drug from office stock - buy and bill)		



## PRIOR AUTHORIZATION REQUEST FORM **EOC ID:**

#### Juvenile Idiopathic Arthritis (OAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name: Supervising Physician:	
☐ Physician office (MEMBER to obtain drug from PHARMACY with a prescription)		
Q5. Is the prescriber a Rheumatologist?		
☐ Yes ☐ No		
Q6. If the diagnosis is POLYARTICULAR JIA, has the patie methotrexate, sulfasalazine, or leflunomide?	ent failed or does the patient have a contraindication to	
☐ Yes ☐ No		
Q7. If the diagnosis is POLYARTICULAR JIA, and the requfailure of an adequate trial, intolerance, or contraindication   Yes  No	·	
Q8. If the diagnosis is POLYARTICULAR JIA, and the refailure of an adequate trial, intolerance, or contraindication	equest is for IV Actemra or Orencia, does the patient have on to Enbrel?	
Q9. If diagnosis is SYSTEMIC JIA, has the patient failed or does the patient have a contraindication to NSAIDs, glucocorticoids, or Kineret?		
☐ Yes ☐ No		
Q10. Additional Comments		
Prescriber Signature	Date	
□ Expedited/Urgent - By checking this box and signing abov	e, I certify that applying the standard review timeframe may	

Lack of the necessary documentation may result in a medical necessity denial. Requesting providers may speak to the SWHP medical

seriously jeopardize the life or health of the enrollee or the enrollee's ability to regain maximum function



# PRIOR AUTHORIZATION REQUEST FORM EOC ID: Juvenile Idiopathic Arthritis (OAA)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:
Patient Name:	Supervising Physician:

director at 1-888-316-7947 regarding the case to have an opportunity to help impact the decision on a request before coverage has been decided.

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document